Is Upstream Bio, Inc. (UPB) a Rising Biotech Opportunity After New Analyst Coverage?
TheFly reported on June 3 that H.C. Wainwright analyst Matthew Caufield initiated coverage of UPB with a Buy rating and a $36 price target.
Upstream Bio Inc. (UPB)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | OrbiMed Advisors Samuel Isaly | 5,693,589 | $39,399,636 | 0.73% | |
| 2. | Decheng Capital Min Cui | 2,724,868 | $18,856,087 | 2.58% | |
| 3. | Enavate Sciences James Boylan | 2,459,703 | $17,021,145 | 4.93% | |
| 4. | Millennium Management Israel Englander | 1,143,775 | $7,914,923 | +23% | 0% |
| 5. | D E Shaw D. E. Shaw | 1,036,044 | $7,169,425 | +27% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $17.00 | 660,000 | $11,220,000.00 | 4,554,873 | 2024-10-15 | Filing | |
| $17.00 | 165,000 | $2,805,000.00 | 1,138,716 | 2024-10-15 | Filing | |
| $17.00 | 660,000 | $11,220,000.00 | 4,554,873 | 2024-10-15 | Filing | |
| $17.00 | 165,000 | $2,805,000.00 | 1,138,716 | 2024-10-15 | Filing | |
| $17.00 | 1,175,000 | $19,975,000.00 | 1,175,000 | 2024-10-15 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.10 | 853 | $5,203.30 | 28,795 | 2026-06-16 | Filing | |
| $6.10 | 2,095 | $12,779.50 | 70,812 | 2026-06-16 | Filing | |
| $6.10 | 700 | $4,270.00 | 23,601 | 2026-06-16 | Filing | |
| $6.10 | 895 | $5,459.50 | 33,197 | 2026-06-16 | Filing | |
| $6.10 | 477 | $2,909.70 | 16,048 | 2026-06-16 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 8,162,897 | $56,487,247 | 0% | |
| 2. | 3,768,619 | $26,078,843 | 0% | |
| 3. | 3,753,358 | $25,973,237 | 0% | |
| 4. | 1,876,734 | $12,986,999 | 0% | |
| 5. | 1,012,044 | $7,013,464 | 0% |
News See All
10 Most Promising Small-Cap Stocks to Buy According to Hedge Funds
Tom Lee of Fundstrat spoke on CNBC's Closing Bell on June 9 about chip stocks, market mood, and the overall picture for stocks.
10 Best Low Priced Stocks to Get Rich in 2026
These days, everyone is focusing on finding ways to get rich. The real catch is when this opportunity comes at a low price.
Upstream Bio Presents New Structural Data on Verekitug, Highlights Unique TSLP Receptor Targeting
Upstream Bio Inc. (NASDAQ:UPB) is one of the best hot stocks to invest in.
12 Best Hot Stocks to Invest In
On September 24, Ryan Detrick, Carson Group chief market strategist, joined CNBC's 'Power Lunch' to discuss why he still expects a strong end-of-year rally.
Upstream Bio, Inc. (UPB): A Bull Case Theory
We came across a bullish thesis on Upstream Bio, Inc. on Value investing subreddit by Dizzy_Drawing_2451. In this article, we will summarize the bulls’ thesis on UPB.
Upstream Bio Initiates Phase 2 Clinical Trial for COPD Drug, Verekitug
Upstream Bio Inc. (NASDAQ:UPB) is one of the best IPO stocks to buy according to Wall Street analysts.
13 Best IPO Stocks to Buy According to Wall Street Analysts
On August 14, Tony Kim, Centerview Partners co-president, joined CNBC's 'Closing Bell: Overtime' to discuss the IPO market and the dealmaking environment.
Hedge Fund Resource Center